The SMART Study is a nationwide clinical trial investigating the treatment of Two-Level Symptomatic Cervical Disc Disease (SCDD).
Park City, Utah – December 4, 2020 - We are pleased to announce that our outpatient surgery center at Masson Spine Institute Park City has been named as an investigational site for Centinel Spine’s SMART study, an FDA clinical trial for two level Prodisc C artificial disc.
THE SMART™ CLINICAL STUDY, sponsored by Centinel Spine will evaluate the safety and efficacy for two level Prodisc C in cervical disc injury. The primary purpose of the study is to show that the prodisc C SK and prodisc C Vivo are at least as safe and effective as a similar, currently marketed cervical disc prosthesis (Mobi-C) to treat symptomatic cervical disc disease (SCDD) in patients at two contiguous levels from C3 to C7.
“This is big news for the Masson Spine Institute Park City, and we are proud to bring the first of many national spine surgical investigational studies to the community of Park City.” – Dr. Robert L. Masson, Spine Surgeon and Founder of the Masson Spine Institute.
MSI Park City is currently enrolling patients interested in a two-level arthroplasty solution who are willing to be included in a landmark investigational trial in the United States.
Visit the SMART™ Clinical Study information page to learn more about the study and patient eligibility.
The Masson Spine Institute is a passionate advocate for prevention, wellness, fitness, and ultimately extreme recovery in the face of spinal injury and encourages patients to become experts in their injury and to continue to ask questions about their injury and their treatment until the strategy makes sense to them. MSI patients are the most prepared for the pathway of recovery because they understand the sacrifices and commitment that they need to make in order to succeed and to become healthy and functionally active.
Centinel Spine, LLC is a privately-held spinal device company leading the development and commercialization of the Stand-Alone, No-Profile, Integrated Interbody fusion technologies. The company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica LLC and Surgicraft LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies and continues its corporate mission of becoming the leading anterior column support spine franchise, providing elegantly simple implants and instruments that are tissue-sparing and generating superior clinical outcomes.